Fetal hemoglobin level and nutritional status in patients with sickle cell disease

Sherif M. Badawy*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Hydroxyurea is the only medication approved by the U.S. Food and Drug Administration for sickle cell disease, and there is strong evidence to support the efficacy and the cost effectiveness of using hydroxyurea is patients with sickle cell disease by increasing fetal hemoglobin levels. It is important to clarify the relationship between patients' nutritional status/intake and fetal hemoglobin levels. In particular, hydroxyurea has been recommended for patients with poor growth, and the recent guidelines from the National Institute of Health suggested offering hydroxyurea to patients as young as nine month old of age.

Original languageEnglish (US)
Article number63
JournalNutrition Journal
Volume15
Issue number1
DOIs
StatePublished - Jul 8 2016

Keywords

  • Fetal hemoglobin
  • Hydroxyurea
  • Nutrition
  • Sickle cell disease

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics

Fingerprint

Dive into the research topics of 'Fetal hemoglobin level and nutritional status in patients with sickle cell disease'. Together they form a unique fingerprint.

Cite this